NC Biotech9h
Beam Therapeutics reports gene editing breakthrough
The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
Zacks Investment Research on MSN15h
Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates
Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.19 per share a year ago. These figures are ...
Zacks Investment Research on MSN16h
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago. These figures ...
Endpoints News18h
Galatea Bio gets $25M to map ge­net­ic di­ver­si­ty of 10 mil­lion peo­ple, help phar­ma cre­ate new med­i­cines
Miami startup Galatea Bio raises $25M to sequence genetic diversity of 10M people globally, focusing on underrepresented ...